$8.38
Today
as of Jul 22, 16:25 ET
Last 30 days
Recent Press Releases & News
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
Xeris Biopharma Holdings Insider Sold Shares Worth $383,176, According to a Recent SEC Filing
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Overview
52-week range
$4.30
$10
71% of range
Avg surprise (last 2)
+40.5%
Avg reaction (last 2)
+9.6%
100% positive
Latest IV / EM
63%
EM ±14.3% · $8 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $0.01 | — | — | +116.7% | +4.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | — | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.01 | $-0.03 | +66.7% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.06 | $-0.07 | +14.3% | — | +15.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.11 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.10 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.14 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.09 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.14 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | $0.02 | -$0.01 | +300.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $8M | — | $7M | $4M | $-3M | — | $-13M | $-8M |
| Net income | $2M | — | $621,000 | $-2M | $-9M | — | $-16M | $-15M |
| EPS (diluted) | $0.01 | — | — | $-0.01 | $-0.06 | — | $-0.11 | $-0.10 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $112M | $111M | $92M | $59M | $58M | $72M | $59M | $58M |
| Inventory | $74M | $69M | $67M | $67M | $53M | $48M | $45M | $43M |
| Total current assets | $252M | $240M | $224M | $186M | $163M | $168M | $163M | $170M |
| Total assets | $392M | $384M | $370M | $335M | $315M | $323M | $321M | $332M |
| Long-term debt | $221M | $220M | $219M | $219M | $218M | $217M | — | — |
| Total liabilities | $379M | $370M | $371M | $354M | $351M | $353M | $349M | $351M |
| Total equity | $13M | $14M | $-861,000 | $-19M | $-35M | $-30M | $-28M | $-19M |